Search

everythinglearnresearchcommunity

for

Search:↓

The user has been on finasteride for 17 months and recently switched to dutasteride, sharing bloodwork results showing no side effects. They express a wish to have started treatment earlier to save their hair.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.

The conversation is about hair transplants in America, specifically the availability of DHI. The user is currently using finasteride and plans to use microneedling, oral castor oil, and eventually undergo FUE or DHI.

A user experienced side effects from finasteride and switched to using GHK-Cu for hairline improvement, noticing some positive changes after three months. They used a 2mg daily dose via subcutaneous injections and reported increased hair density and baby hairs, though results were not dramatic.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The user is confused about the pricing and concentration of pyrilutamide powder for hair loss treatment. They calculate that 500mg of pyrilutamide can make ten 1ml applications of a 5% solution, costing $119.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

Dutasteride isn't effectively reducing DHT levels, prompting a switch back to finasteride. The user questions the reliability of their DHT test results due to hair loss concerns.

The conversation is about starting finasteride for hair loss, with concerns about high free testosterone and potential side effects like gynecomastia. The user plans to address vitamin deficiencies before beginning the treatment.

A 20-year-old with thinning hair has low vitamin D and normal testosterone. They are prescribed oral minoxidil and vitamin D, and are questioning if finasteride is also necessary.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Hair loss discussion mentions Verterporfin for scar-free healing and hair follicle regeneration. Human study expected within 2 years.

A user is considering using 70% isopropyl alcohol with glycerin as a carrier for topical finasteride for hair loss but is concerned about its safety compared to ethanol. They are unsure where to buy ethanol without toxic methanol.

The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

The conversation discusses verteporfin as a potential hair loss treatment and questions why more precise methods aren't used to test its effectiveness in regrowing hair. Some users believe verteporfin is promising and should receive more attention, while others are skeptical about the testing methods.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.